A5056354028- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Colorectal Cancer Surgical Treatments
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- Colorectal Cancer Screening and Detection
- Cancer Diagnosis and Treatment
- Atrial Fibrillation Management and Outcomes
- Iron Metabolism and Disorders
- Viral-associated cancers and disorders
- Porphyrin Metabolism and Disorders
- Esophageal and GI Pathology
- Pancreatic and Hepatic Oncology Research
- Therapeutic Uses of Natural Elements
- Medical Imaging Techniques and Applications
- Genetic factors in colorectal cancer
- Nutrition and Health in Aging
- Colorectal Cancer Treatments and Studies
- Medical Imaging and Pathology Studies
Memorial Sloan Kettering Cancer Center
2016-2024
Cornell University
2021
Albert Einstein College of Medicine
2013-2018
Montefiore Medical Center
2012-2015
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset cancer caused deficiency in mismatch repair. Because repair-deficient colorectal responsive to programmed death 1 (PD-1) blockade context metastatic disease, it was hypothesized that checkpoint could be effective patients with repair-deficient,
SUMMARY The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung cancer. It plays important roles promoting oncogenesis cancer and mediating resistance to EGF receptor tyrosine kinase inhibitors. Targeted agents against the components of this are currently development their clinical benefits remain be defined. This review provides an overview dysregulation novel targeting In addition, potential predictive biomarkers guiding patient selection for targeted inhibition also discussed.
62 Background: Trastuzumab stimulates HER2-specific T cell responses and increases tumor PD-L1 expression, anti-PD-1 antibody can help enhance cell-specific immunity of trastuzumab. Oxaliplatin further T-cells by activating dendritic cells. We conducted a phase II trial pembrolizumab with chemotherapy/trastuzumab. Methods: Patients previously untreated HER2 IHC 3+ or FISH+ tumors irrespective status received intravenous P 200 mg flat dose, 6 mg/kg (after 8 load), O 130 mg/m2 every 3 weeks...
Background Patients with germline/somatic BRCA1/BRCA2 mutations (g/s BRCA1/2 ) comprise a distinct biologic subgroup of pancreas ductal adenocarcinoma (PDAC). Methods Institutional databases were queried to identify patients who had PDAC g/s . Demographics, clinicopathologic details, genomic data (annotation s according precision oncology knowledge base for somatic mutations), zygosity, and outcomes abstracted. Overall survival (OS) was estimated using the Kaplan‐Meier method. Results In...
16 Background: Total neoadjuvant therapy with induction chemotherapy and chemoradiation (chemoRT) is the standard treatment for locally advanced rectal adenocarcinomas. Mismatch repair deficient (dMMR) tumors respond poorly to chemotherapy. PD-1 blockade effective in patients metastatic dMMR colorectal cancers, but its efficacy has not been established setting. The purpose of this study evaluate clinical benefit cancer. Methods: We designed a prospective, single-arm, phase II which stage III...
<h3>Importance</h3> Predicting outcomes in patients receiving neoadjuvant therapy for rectal cancer is challenging because of tumor downstaging. Validated clinical calculators that can estimate recurrence-free survival (RFS) and overall (OS) among with who have received multimodal are needed. <h3>Objective</h3> To develop validate providing estimates recurrence better individualized decision-making than the American Joint Committee on Cancer (AJCC) staging system or (NAR) score. <h3>Design,...
To determine the safety and efficacy of adding anti-PD-L1 antibody durvalumab to induction FOLFOX preoperative chemotherapy in locally advanced esophageal adenocarcinoma.
Importance Clonal hematopoiesis (CH) has been associated with development of atherosclerosis and leukemia worse survival among patients cancer; however, the association cancer therapy efficacy, in particular immune checkpoint blockade (ICB), toxicity not yet established. Given widespread use ICB critical role hematopoietic stem cell–derived lymphocytes play mediating antitumor responses, CH may be therapeutic efficacy hematologic toxicity. Objective To determine between outcomes, toxicity,...
4011 Background: Trastuzumab stimulates HER2-specific T cell responses and increases tumor PD-L1 expression, anti-PD-1 antibody can help enhance cell-specific immunity of trastuzumab. We conducted a phase II trial pembrolizumab with chemotherapy/trastuzumab. Methods: Patients (pts) previously untreated HER2 IHC 3+ or FISH+ tumors irrespective status received intravenous P 200 mg flat dose, 6 mg/kg (after 8 load), O 130 mg/m2 every 3 weeks oral C 850 2 on/1 week off. 22 pts 1 cycle induction...
355 Background: We previously evaluated adding D, an anti-PD-L1 antibody, to PET-directed CRT and found the combination be safe promising in terms of pathologic response survival outcomes. 1 Here, we add T combination. Methods: Pts with locally advanced esophageal/GEJ adenocarcinoma were enrolled. received 2 cycles mFOLFOX6 prior repeat PET/CT. PET responders (≥35% reduction SUV (PETr)) 5-FU/capecitabine oxaliplatin RT, while induction non-responders (PETnr) carboplatin/paclitaxel RT. All...
Background: Abdominoperineal resection (APR) has been advocated for persistent or recurrent disease after failure of chemoradiation (CRT) anal squamous cell cancer (SCC). Treatment with salvage APR can potentially achieve a cure. This study aimed to analyze oncological outcomes in recent time period at comprehensive center. Methods: A retrospective review all patients who underwent biopsy-proven SCC between 1 January 2007 and 31 December 2020 was performed. Patients stage IV the initial...
Some patients with previously treated, unresectable, recurrent or metastatic head and neck malignancies are not amenable to curative-intent treatment. Here, we investigated the quad-shot (RTOG 8502) regimen of hypofractionated proton radiotherapy (RT) in that patient population. From 2013 2015, 26 cancers were treated palliative RT quad shot (3.7 Gy twice daily for 2 days). Patient characteristics survival data reviewed. Seventeen (65%) received ≥ 3 cycles 23 (88%) had prior RT. Overall...
4029 Background: Induction FOLFOX followed by PET-directed CRT prior to surgery demonstrated positive results in the CALGB 80803 study. We investigated safety and efficacy of adding D, an anti-PD-L1 antibody, CRT. Methods: Patients (pts) with locally advanced esophageal/GEJ adenocarcinoma were enrolled. Pts received 2 cycles mFOLFOX6 repeat PET/CT. PET responders (≥35% reduction SUV (PETr)) 5-FU/capecitabine oxaliplatin RT 50.4Gy, while induction non-responders (PETnr) carboplatin/paclitaxel...
405 Background: PEGPH20 (P) degrades hyaluronan (HA), a key component of pancreatic adenocarcinoma (PDAC) tumor microenvironment, leading to reduction interstitial pressure, decompression blood vessels and improvement in delivery chemotherapeutics. A prior study P with chemotherapy PDAC (HALO-202) found an increased risk thromboembolic (TE) events, 43%, effectively reduced subcutaneous enoxaparin treatment. Rivaroxaban (R) is safe effective oral anticoagulant for treating cancer-related TE....
226 Background: Based on the positive results of CALGB 80803 study (J Clin Oncol 2017;35:1 [abstr]), we have added D to induction FOLFOX and pre-op CRT. Methods: Patients (Pts) had T any N+ or T3-4N M0 esophageal Siewert Type I-III GEJ adenocarcinoma staged by EUS, PET/CT CT. Pts received mFOLFOX6 ×2 prior repeat PET/CT. PET responders (PETr) 5-FU capecitabine oxaliplatin with RT 50.4Gy, while non-responders (PETnr) carboplatin/paclitaxel RT. All 1,500 mg q4W starting 2 wks during...
Background: The watch-and-wait strategy provides an opportunity to pursue non-operative management in rectal cancer patients with clinical complete response after neoadjuvant therapy. of those near remains controversial. Objective: We assessed the oncologic outcomes managed by versus total mesorectal excision according Design: Retrospective cohort study. Settings: Comprehensive center New York. Patients: Patients adenocarcinoma diagnosed between January 2006 December 2020. Interventions: A...
6064 Background: Chemoradiotherapy is an accepted standard for patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Although acute long-term toxicities this approach are known, little known about early mortality associated curative-intent treatment. Methods: We reviewed 45 phase III trials radiotherapy in SCCHN published from 2000-2012 adequate reporting defined as deaths during within 3 months therapy, regardless attribution. estimated pooled...